Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Conditions
Interventions
LY4214835
Locations
6
United States
Invicro
New Haven, Connecticut, United States
Boston Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital (MGH)
Charlestown, Massachusetts, United States
BAMF Health Inc.
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Ichor Research
Syracuse, New York, United States
Start Date
December 22, 2025
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
April 17, 2026
NCT00104325
NCT03206060
NCT07470866
NCT07388667
NCT06608446
NCT07542041
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions